September 2014

Fertility expert warns low cost IVF may cost taxpayers more

Posted: 12/09/2014 10:45:27 AM
An approach to ‘more affordable’ IVF in Australia will potentially come at a higher cost per baby to Medicare and therefore the outcomes from these approaches need to be properly evaluated and compared to usual IVF treatment, according to leading IVF exper and Genea Medical Director Associate Professor Mark Bowman.

Media Contact

Alice Ross
M: 0421 741 737
E: alice.ross@genea.com.au

About Genea

Genea is one of Australia’s leading providers for infertility, IVF and other assisted conception treatment with 31 years of experience in the field. The company has long been a fertility pioneer, with research and technologies developed in-house virtually doubling IVF success rates in the mid-nineties and continuing to improve outcomes today. In September 2017, Genea was listed in the Australian Financial Review’s Top 50 Most Innovative Companies List, ranking number 25.